Previous retrospective studies have shown that surgical quality affects local control in rectal cancer..
R
andomized clinical trials have shown that preoperative chemoradiotherapy (CRT) or short-course radiotherapy (RT) before surgery improve local control in locally advanced rectal cancer.
1-3 Total mesorectal excision (TME)
constitutes the current surgical treatment of choice for rectal cancer. 4 The pathology studies by Quirke and colleagues [5] [6] [7] have demonstrated variability in the completeness of resected TME specimens. Three grades of TME quality have been defined, including the mesorectal plane (good-quality, complete, and smooth), intramesorectal plane (moderatequality, nearly complete, and moderately irregular), and muscularis propria plane (poor-quality, incomplete, and severely irregular). 6 Several studies have revealed that the quality of TME greatly determines long-term local control, but most studies consisted of retrospective series, whereas, to our knowledge, phase 3 trial evidence was only provided in the CR07 study. [8] [9] [10] [11] [12] [13] The clinical relevance of the circumferential resection margin (CRM) after TME in rectal cancer has been described in several series. 8, [14] [15] [16] [17] In a meta-analysis of more than 17 500 patients, Nagtegaal and Quirke 18 showed that a tumor involvement of CRM (≤1 mm) was a predictor for both local and distant recurrence and overall survival (OS). 18 The Magnetic
Resonance Imaging and Rectal Cancer European Equivalence (MERCURY) study showed that high-resolution magnetic resonance imaging (MRI) enabled accurate staging, including the detection of CRM involvement that strongly correlated with worse disease-free survival (DFS) and local control rates. 19 However, most previous reports were characterized by a relatively small sample size and retrospective nature, and phase 3 trial confirmation of the long-term effect of TME quality on local control, as initially reported in the CR07 trial, is lacking. In this study, we aimed to investigate the association of TME quality with clinical and pathologic parameters and its association with the clinical outcome as part of the large CAO/ARO/ AIO-04 phase 3 trial. This randomized clinical trial assessed the clinical effect following the addition of oxaliplatin to 5-fluorouracil-based preoperative CRT and adjuvant chemotherapy. 20 , 21 The quality of TME was recorded prospectively in both arms of the trial using the system by Quirke and colleagues.
5-7
Methods
Study Design and Participants
The CAO/ARO/AIO-04 trial was a multicenter, 2-arm randomized phase 3 study. Its design and details have been previously reported. 20, 21 The trial had approval by the local ethics committee of the University of Erlangen, Germany. Participants provided written informed consent. A description is shown in the eMethods in Supplement 1 and the eFigure 1 in Supplement 1 illustrates the treatment plan. The full trial protocol is provided in Supplement 2.
Pathologic Examination of Resected Specimen
A standardized pathology protocol for resected specimens was developed by the committee of reference pathologists (C.W.,
A.H., and P.S.). 20 Preparation, processing and analysis of the resected specimens has been reported in detail before. 22 , 23 The quality of TME plane (mesorectal, intramesorectal, and muscularis propria plane) was scored according to Quirke et al. 8 Examples of TME planes are shown in eFigure 2 in Supplement 1. In addition to the pathologist-based evaluation, the quality of TME plane was also prospectively scored by the operating surgeon. A central pathology review of resected specimen was not performed. The follow-up process has been described in detail in eMethods in Supplement 1.
Statistical Analysis
Disease-free survival was defined as the time between patient randomization and either the formation of a macroscopically visible tumor following surgery (R2 resection), locoregional recurrence after an R0/1 resection, distant metastases or progression, or death from any cause, whichever occurred first. The cumulative incidence of locoregional and distant recurrences were defined as the time between patient randomization and the occurrence of any locoregional or distal recurrence, irrespective of whether this was a first event. The time from patient randomization to death from any cause was used to calculate OS. The correlation of TME plane with clinicopathologic factors was assessed using the χ 2 test. This test was used to test the association of pathologist-based evaluation with surgeonbased evaluation of TME plane. A univariable analysis using the log-rank test was performed to investigate the prognostic value of TME, the treatment arm, pretreatment clinicopathologic factors, and postsurgical pathologic factors. The hazard ratios (HRs) and corresponding P values of the TME intergroup comparisons of intramesorectal vs mesorectal TME and muscularis propria vs mesorectal TME were calculated using a Cox regression model. A multivariable analysis for OS, DFS, locoregional, and distant recurrence was conducted using Cox regression models. Patients with missing values in 1 or more of the variables (TME, treatment arm, local resection status, or pathologic stage) were excluded. A P value of less than .05 was considered significant. Statistical analyses were performed with SPSS, version 20 (SPSS Inc) and R, version 3.4 (R Foundation).
Results

Patient Characteristics and Association of TME With Clinicopathologic Factors
In total, 1265 patients were recruited for trial between July 25, 2006, and February 26, 2010. The Consolidated Standards of Reporting Trials diagram is shown in Figure 1 . Total mesorectal excision quality as assessed by the pathologist was available for 1152 patients (eTable 1 in Supplement 1). The plane of surgery was comparable in the 2 treatment arms (mesorectal vs intramesorectal vs muscularis propria: 5-fluorouracil [FU] , 80.8% vs 14.3% vs 4.9%, respectively; 5-FU + oxaliplatin, 80.7% vs 15.1% vs 4.3%, respectively; P = .82). Total mesorectal excision quality was significantly worse in patients with a more advanced cT category (mesorectal vs intramesorectal vs muscularis propria: cT2, 78.7% vs 21.3% vs 0%, respectively; cT3, 81.9% vs 14.1% vs 4.0%, respectively; cT4, 69.2% vs 16.7% vs 14.1%, respectively; missing, 40.0% vs 16.1% vs 4.8%, respectively; P < .001), lymph node involvement (mesorectal vs intramesorectal vs muscularis propria: cN0, 85.8% vs 0.4% vs 3.8%, respectively; cN1, 79.1% vs 16.1% vs 4.8%, respectively; P = .04), and tumors in the lower third of the rectum (mesorectal vs intramesorectal vs muscularis propria: distance from the anal verge of 0-5 cm, 72.6% vs 19.9% vs 7.4%, respectively; P < .001). There was no correlation between TME plane and any of the other factors (eTable 1 in Supplement 1).
We next examined the correlation between pathologistbased evaluation and surgeon-based evaluation of TME plane quality (eTable 2 in Supplement 1). Compared with the pathologist-based mesorectal plane TME, surgeon-based evaluation showed agreement in 827 cases (86.4%). In contrast, a significant discrepancy was observed for intermesorectal plane, as only 68 surgeon-based evaluations (56.2%) of TME plane were in agreement with the pathologist assessment. For muscularis propria, agreement in TME plane quality evaluation occurred in 15 cases (75%).
Low anterior resection was associated with a significantly better plane of surgery compared with intersphincteric or abdominoperineal resection (mesorectal vs intramesorectal vs muscularis propria: anterior resection, 86.0% vs 11.3% vs 2.7%, respectively; abdominoperineal extirpation, 67.0% vs 23.0% vs 10.0%, respectively; intersphincter resection, 86.7% vs 13.3% vs 0%, respectively; other, 64.0% vs 24.0% vs 12.0%, respectively; P < .001). Similarly, the plane of surgery was significantly worse in patients with advanced ypT category (mesorectal vs intramesorectal vs muscularis propria: ypT0, 83.6 vs 12.2% vs 4.2%, respectively; ypT1/Tis, 90.5% vs 8.3% vs 1.2%, respectively; ypT3, 78.4% vs 16.1% vs 5.6%, respectively; ypT4, 50.0% vs 30.6% vs 19.4%, respectively; P < .001) and advanced ypN category (mesorectal vs intramesorectal vs muscularis propria: ypN, 82.2% vs 13.3% vs 4.5%, respectively; ypN1, 80.2% vs 16.3% vs 3.5%, respectively; ypN2, 69.8% vs 21.9% vs 8.3%, respectively; missing, 100.0% vs 0% vs 0%, respectively; P =.04)( Table 1) .
Involvement of CRM (≤1 mm) was found in 35 patients (6.2%) who were treated in the standard arm and in 32 patients (6.1%) in the experimental arm. An involved CRM occurred in 39 of 930 patients (3.7%) after mesorectal TME surgery, in 13 of 169 (7.6%) after intramesorectal, and in 10 of 53 patients (18.9%) after muscularis propria, respectively (P < .001) ( Table 2) . Circumferential resection margin involvement occurred in 31 of 729 patients (4.3%) who received low anterior resection, 26 of 276 patients (9.4%) after undergoing abdominoperineal resection, 3 of 52 patients (5.8%) after undergoing intersphincteric resection, and in 7 of the 29 patients (24%) who underwent an operation conducted with another surgical method (P < .001).
Prognostic Value of TME for Clinical Outcomes
The median follow-up was 50 (interquartile range, 38-61) months. Treatment in the experimental arm was a predictor for a superior 3-year DFS (5-FU CRT vs 5-FU/oxaliplatin CRT, 71.2% vs 75.9%, respectively; P = .03), the cumulative incidence of distant metastases (23.1% vs 19.2%; P = .04), and the cumulative incidence of local recurrences after R0/R1 resection (4.9% vs 3.2%; P = .01). A significantly better 3-year DFS and cumulative incidence of distant metastases correlated significantly with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (ECOG 0 vs ECOG 1 +2, 76.8% vs 63.4%, respectively, and 19.0% vs 29.15, respectively; P < .001 for both), early cT category (cT2 vs cT3 vs cT4, 77.7% vs 74.8% vs 56.7%, respectively, and 12.9% vs 20.4% vs 34.85, respectively; P < .001 for both) and low tumor grading (G1 vs G2 vs G3, 68.2% vs 75.7% vs 56.8%, respectively, and 21.8% vs 19.4% vs 35.9%, respectively; P < .001 and P = .001, respectively), whereas tumors located 0 to 5 cm from the anus were associated with a higher metastatic propensity (0-5 cm vs 5-10 cm vs >10 cm, 25.3% vs 19.2% vs 18.8%, respectively; P = .04). Age that was younger or equal to the median (age <63.6 years vs >63.6 years, 86.1% vs 90.5%, respectively; P = .01), an ECOG performance status of 0 (ECOG 0 vs ECOG1+2 ,9 0 . 8 %v s 79.3%, respectively; P < .001), early cT category (cT2 vs cT3 vs CT4, 87.7% vs 89.1% vs 80.3%, respectively; P = .01), and low tumor grading (G1 vs G2 vs G3, 93.1% vs 89.9% vs 71.7%, respectively; P < .001) were associated with significantly better 3-year OS. A higher incidence of local recurrence was observed in patients with worse ECOG status (ECOG 0 vs ECOG 1+ 2, 3.4% vs 7.2%, respectively; P = .01) (eTable 3 in Supplement 1).
We next examined the prognostic role of post-CRT patient and tumor factors for all 4 clinical end points in a univariable analysis ( Table 3 ). The quality of TME plane was significantly associated with 3-year DFS (mesorectal vs intramesorectal vs muscularis propria, 75.9% vs 68.4% vs 67.2%, respectively; P = .01, Figure 2A ) the 3-year cumulative incidence of distant metastases (mesorectal vs intramesorectal vs muscularis propria, 19.7% vs 25.5% vs 27.6%, respectively; P = .03; Figure 2B ), local recurrence after undergoing an R1/R0 resection (mesorectal vs intramesorectal vs muscularis propria, 3.2% vs 4.8% vs 12.0%, respectively; P < .001, Figure 2C ) and OS (mesorectal vs intramesorectal vs muscularis propria, 90.3% vs 85.1% vs 89.7%, respectively; P = .02, Figure 2D ). Notably, mesorectal vs muscularis propria TME was associated with significantly lower local recurrence rates (HR = 4.19; P < .001), whereas local recurrence after mesorectal TME was not significantly different compared with intramesorectal quality (HR = 1.47; P = .30). In total, 185 patients (16.0%) presented with pathological complete response but the univariate analysis failed to demonstrate a significant association of TME quality with either DFS (mesorectal vs intramesorectal vs muscularis propria TME, 93.2 % vs 86.4% vs 87.5%, respectively; P = .75), the cumulative incidence of distant metastases (mesorectal vs intramesorectal vs muscularis propria TME, 3.4% vs 9.1% vs 12.5%, respectively; P = .41), local recurrence (mesorectal vs intramesorectal vs muscularis propria TME, 4.1% vs 4.5% vs 12.5%, respectively; P =.12)orOS (mesorectal vs intramesorectal vs muscularis propria TME, 95.9% vs 100% vs 87.5%, respectively; P = .28) in this subgroup.
Furthermore, abdominoperineal resection was associated with significantly worse 3-year DFS (anterior resection vs abdominoperineal resection vs intersphincteric vs other, 77.4% vs 66.5% vs 80.8% vs 56.5%, respectively; P < .001), cumula- In the multivariable analysis (Table 3) , the plane of surgery (mesorectal vs muscularis propria TME) was an independent factor for the cumulative incidence of local recurrence (mesorectal vs muscularis propria: HR, 3.72; 95% CI, 1.59- (HR, 0.76; 95% CI, 0.61-0.95; P = .02) and a lower incidence of local recurrences after R0/R1 resection (HR, 0.43; 95% CI, 0.23-0.80; P = .01). Complete resection status was associated with significantly superior outcomes for all 4 clinical end points. We failed to detect any further significance in multivariable analyses (Table 3) . As CRM has been reported to majorly affect local control, 18 we performed an additional multivariable analysis that also included CRM on exclusion of all missing CRM cases to avoid statistical bias (eTable 4 in Supplement 1). Importantly, TME plane quality remained an independent prognostic factor for local recurrence (mesorectal vs muscularis propria: HR, 2.62; 95% CI, 1.11-6.18; P = .03), whereas CRM involvement (>1 mm vs ≤1 mm) was a predictor for worse DFS (HR, 1.58; 95% CI, 1.08-2.31; P = .02) and local recurrence (HR, 3.60; 95% CI, 1.66-7.79; P = .001).
Discussion
Total mesorectal excision represents the surgical technique of choice for treating rectal cancer. 4, 24 Here, we investigated the prognostic role of the TME plane quality in patients with rectal cancer who were treated within the CAO/ARO/AIO-04 phase 3 randomized clinical trial. Of the 1152 patients with known quality of TME plane, 930 (80.7%) had pathologistconfirmed mesorectal (good) quality of surgery. This aligns with data from modern clinical trials comparing open vs laparoscopic surgery that showed mesorectal TME in approximately 80% to 90% of patients 25, 26 and exceeds the 52% and 56% reported in the MRC CR07 8 and the Dutch Colorectal Cancer Group 9 phase 3 studies. Leonard et al 10 reported a mesorectal TME plane in 875 of 1382 resections (63%) based on the Belgian PROCARE database. Data similar to the PROCARE analysis were also reported by Leite et al 13 and Maslekar et al.
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The difference could in part be attributed to the different chronological periods of study conductance, as surgical training has evolved significantly during the last decade. The roles of surgery and pathologists are key, as they both influence treatment decisions and clinical outcomes in rectal cancer. 27 In accordance with previous studies, TME was an independent prognostic factor for local recurrence. Although several reports have previously demonstrated the importance of an optimal TME plane for clinical outcomes, to our knowledge, only the CR07 trial by Quirke and colleagues 8 has reported the prognostic effect of TME plane within a phase 3 study. Short-course radiotherapy resulted in a reduced local recurrence rate by more than 50% for all 3 TME planes, whereas the reduction in local recurrence rate postradiotherapy was most pronounced in the mesorectal TME plane group (HR = 4.5), indicating that patients benefit mostly when the best surgical procedure is combined with preoperative radiotherapy. 8 In the comparison of pathologist-based vs surgeon-based evaluation of TME quality, we found a relatively high agreement (86.4%) in the mesorectal TME group but a significant discrepancy for intermesorectal plane (56.2%), emphasizing the importance of pathologist training for accurate prognostication of surgical outcomes.
27-29 To our knowledge, such a direct prospective comparison of pathologist-based vs surgeonbased evaluation of TME quality has not been reported before. An advanced pathologic stage and abdominoperineal resection correlated with a worse quality of surgery in this trial. Some studies, including the MRC trial, have reported a lack of correlation between the pathologic stage and/or surgical tech- Abbreviations: CRT, chemoradiotherapy; DFS, disease-free survival; HR, hazard ratio; OS, overall survival; Ox, oxaliplatin; TME, total mesorectal excision; 5-FU, 5-fluorouracil.
a Patients with R2-resection were also included in the multivariate analysis for cumulative incidence of distant metastases and overall survival. nique with the plane of surgery, indicating that surgical skills greatly determine the pathologic outcome, 8 whereas other series have found strong association. 30 The variability observed could be attributed to the different cohorts and the training of individual surgeons. 4 ,31,32 Also, there is an ongoing discussion as to whether more extensive surgical procedures, such as posterior pelvic exenterations, should be considered for bulky tumors of the lower third of rectum. 11, 16, 30 We failed to observe a significant association between TME plane quality and OS in a multivariable analysis. Nagtegaal et al 9 have revealed OS rates of 86% and 76% for mesorectal and muscularis propria plane, respectively (P < .05) in univariable analysis, whereas this association was not assessed in the multivariable analysis. A study by Maslekar et al 12 did not find a significant association between surgical quality and OS. Circumferential resection margin involvement strongly correlated with worse clinical outcomes in our cohort, in line with the meta-analysis data found for more than 17 000 patients by Quirke and Nagtegall. 18 In that report, involved CRM was found to be more common in patients with advanced stage, ulcerative growth patterns, poor differentiation, vascular invasion, poor TME quality, abdominoperineal resection for tumors of lower third of rectum, and female sex. 18 It has been hypothesized that CRM positivity possibly reflects more aggressive tumors that fail to respond to preoperative CRT. In the MERCURY study, Taylor et al 19 used MRI for precise disease A, Disease-free survival (intramesorectal vs mesorectal TME: hazard ratio [HR], 1.35; 95% CI, 1.01-1.80; P = .04; muscularis propria vs mesorectal TME: HR, 1.73; 95% CI, 1.13-2.66; P = .01; global P = .01). B, Cumulative incidence of distant metastases (intramesorectal vs mesorectal TME: HR, 1.34; 95% CI, 0.97-1.86; P = .08; muscularis propria vs mesorectal TME: HR, 1.69; 95% CI, 1.04-2.75; P = .03; global P = .03). C, Cumulative incidence of local recurrence (intramesorectal vs mesorectal TME: HR, 1.47; 95% CI, 0.71-3.06; P = .3; muscularis propria vs mesorectal TME: HR, 4.19; 95% CI, 1.94-9.05; P = .0003; global P < .001). D, Overall survival according to the TME plane (intramesorectal vs mesorectal TME: HR, 1.52; 95% CI, 1.04-2.21; P = .03; muscularis propria vs mesorectal TME: HR, 1.77; 95% CI, 1.00-3.14; P = .05; global P = .02). A univariable analysis was performed using the log-rank test. The HRs and corresponding P values of the TME intergroup comparisons (intramesorectal vs mesorectal TME, indicated by the blue lines; muscularis propria vs mesorectal TME, indicated by the red lines) were calculated using a Cox regression model.
staging and demonstrated an adverse clinical association with positive CRM. Notably, in our series, the quality of TME plane remained an independent prognostic factor for local recurrence in the separate multivariable analysis that also included CRM.
Limitations
We acknowledge the limitations of our study. First, there was no central pathology review. The PROCARE study compared the quality of TME specimens as assessed by a central review panel and local pathologists for more than 250 patients with rectal cancer 33 and found no major discrepancies, whereas the prediction of clinical outcomes was comparable. Hence, under the prerequisite of adequate pathologist training, a central review may not have led to a significant correction of individual pathology reports. 28,33 Second, baseline MRI results
were not compulsory in this trial and the relevance of MRIdefined staging in the context of TME quality could not be explored. Third, the trial was conducted during a period when open surgery was still standard in Germany, whereas laparoscopic or robotic surgery were only scarcely performed; hence, comparison of the outcome after open vs laparoscopic (or robotic) surgery cannot be conducted in our series.
Conclusions
Good-quality TME was associated with significantly better local control independently of other clinicopathologic factors, including CRM. This phase 3 randomized clinical trial confirms the long-term clinical association of TME plane quality with local recurrence as initially reported in the MRC CR07 study. 8 Our secondary end point analysis adds high-level clinical evidence and highlights the roles of surgeons and pathologists in managing rectal cancer. Continuous training should be encouraged to further enhance surgical skills. 
eMETHODS Study design and participants
Patients with rectal adenocarcinoma up to 12 cm above the anal verge with cT3-4 and/or lymph node-positive disease were randomly assigned to receive either standard 5-FU-based CRT (control arm) or oxaliplatin plus 5-FU-based preoperative CRT (investigational arm). Postoperative chemotherapy was administered in both study arms. Surgery was performed 5-6 weeks after completion of CRT using TME, and postoperative chemotherapy was initiated 4 weeks after surgery. Randomization was performed using computer-generated blockrandomization codes stratified by center, clinical T category (cT1-4 vs cT4), and clinical N category (cN0 vs cN1-2) without masking. DFS was the primary endpoint. We hypothesized that addition of oxaliplatin would improve the primary endpoint DFS improve from 75% in the control arm to 82% in the investigational arm at 3-years (hazard ratio of 0.81). The sample size required in this trial was 1200 patients using a power of 80% and a type I error of 5%. Secondary endpoints included the plane (quality) of TME surgery, pathological complete response, resection status, the proportion of patients having R0 resection, the number of patients having sphincter-sparing surgery, overall survival, local and distant recurrence, acute and late toxicity. Safety and compliance analyses included patients as treated, efficacy endpoints were examined using the intention-to-treat principle. The trial registration number was number NCT00349076 (ClinicalTrials.gov).
Follow-up
Follow-up examinations were performed at 3-month intervals during the first 2 years after surgical operation, and then annually up to 5 years. Follow-up included patient history, physical examination, ultrasound of the abdomen, and serum carcinoembryonic antigen. Computed tomography of the abdomen and pelvis was repeated 3 months after treatment completion. Colonoscopy was conducted at 6 months if previously omitted, otherwise at 1 year and 5 years. Chest radiography was performed on an annual basis up to a total of 5 years posttreatment. Histological confirmation was advocated in case of suspicious clinical and radiological findings indicating locoregional and/or distant recurrence. Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; 5-FU, 5-fluorouracil; Ox, oxaliplatin; TME, total mesorectal excision; CRT, chemoradiotherapy; pCR, pathologic complete response;
*Patients with R2-resection were also included in the multivariate analysis for cumulative incidence of distant metastases and overall survival
Selection of Patients, including both Eligibility and Ineligibility Criteria
Patients matching all inclusion criteria and none of the exclusion criteria listed below will be recruited in 88 participating centers.
Inclusion Criteria:
Males and females aged ≥ 18 years, inclusive, at screening Histologically proven, advanced primary carcinoma of the rectum (tumor > 12cm above the anal verge), with clinically staged T3/4 or any node-positive disease No prior cancer-specific therapy except a diverting stoma ECOG PS ≤ 2 Adequate bone marrow function: Leukocytes > 3,5 x 10^9/L, absolute Neutrophil count > 1,5 x 10^9/L, Platelet count > 100 x 10^9/L, Hemoglobin > 10 g/dL Adequate hepatic function: Total bilirubin < 2,0 mg/dL ALAT, ASAT, alkaline phosphatase, gamma-GT < 3 x ULN 7. Serum creatinine < 1,5 mg/dL, creatinine clearance > 50 mL/min Written informed consent by the competent patient Exclusion Criteria: Pregnant or breast feeding women Fertile patients without adequate contraception during therapy Past or ongoing drug abuse or alcoholic excess Prior application of chemotherapy Prior application of radiotherapy to the pelvis Prior (within 4 weeks) or concurrent treatment with any other investigational agent Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule History of severe somatic or psychological diseases: -instable cardiac disease not well controlled with medication, myocardial infarction within the last 6 months:* Central nervous system disorders or psychiatric disability including dementia or epileptic disease; * active uncontrolled intercurrent infections or sepsis Peripheral neuropathy > 2 (NCI CTC AE grading) Previous or concurrent malignancies, with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. The inclusion of patients with other adequately treated tumors within the last 5 years has to be discussed with the principal investigator Chronic diarrhea (> NCI CTC AE-Grade 1) Known allergy to substances containing platinum compounds Concurrent use of the antiviral agent sorivudine or chemically related analogues Known dehydropyrimidindehydrogenase (DPD) deficiency
Schema and Treatment Plan, including Administration Schedule
Overview
This is a multi-center, open-label, parallel-group, randomized, phase III treatment trial in patients with histologically proven advanced primary adenocarcinoma of the rectum (tumor < 12cm from the anal verge) with clinically staged T3/4 or any node-positive disease Approximately 1200 patients in 88 participating centers in Germany will be randomly assigned to receive either Experimental Arm A (800 patients): Preoperative simultaneous chemoradiotherapy (5-Fluorouracil and Oxaliplatin), TME-surgery, and adjuvant chemotherapy (oxaliplatin, calciumfolinat, 5-Fluorouracil) or Active Comparator Arm B (800 patients): Preoperative simultaneous chemoradiotherapy (5-Fluorouracil), TME-surgery, and adjuvant chemotherapy (5-Fluoruracil). 
Schedule of Events
Pre-Treatment
Informed Consent
Informed Consent is obtained prior to any study-specific screening procedures.
Screening:
Assessment of eligibility to ensure all inclusion-and none of the exclusion criteria are met.
Randomization:
Random treatment assignment is performed centrally and is stratified by study center, clinical T-category (cT1-3/cT4), and clinical N-category (cN0/cN1-2).
Treatment Arm A (Experimental):
Preoperative Radiotherapy Radiotherapy consists of 28 daily fractions; single dose: 1.8 Gy per day, Monday through Friday, for 5 weeks. Total dose: 50.4 Gy, delivered with a minimum of 6 MV photons through a three-or four-field box technique to the primary tumor, mesorectal, presacral and internal iliac lymph nodes up to the level of the promontorium. 
Preoperative Concurrent Chemotherapy
Recovery
There is a recovery period of 5-6 weeks after chemoradiotherapy.
Surgery
Total mesorectal excision is performed according to a standardized technique.
Recovery
There is a recovery period of 4 weeks after surgery.
Adjuvant Chemotherapy
Oxaliplatin: 100 mg/m² iv on day 1; calciumfolinat: 400 mg/m² on Day 1; 5-Fluorouracil: continuous intravenous (civ) infusion of 2400 mg/m² over 46 hours; repeat Day 15, 8 cycles.
Arm B (Active Comparator):
Preoperative Simultaneous Radiotherapy Radiotherapy consists of 28 fractions; single dose: 1.8 Gy once per day, Monday through Friday, for 5 weeks. Total dose: 50.4 Gy. Radiotherapy is delivered with a minimum of 6 MV photons through a three-or four-field box technique to the primary tumor, mesorectal, presacral and internal iliac lymph nodes up to the level of the promontorium.
Preoperative Concurrent Chemotherapy:
Concurrent chemotherapy with Fluorouracil: Administration during W e e k 1 a n d 5 o f preoperative radiotherapy: civ infusion over 120 h with 1000 mg/m² (on Days 1-5 and 29-33), 4 cycles
Recovery
Surgery
Recovery
Adjuvant Chemotherapy 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) iv bolus for 2-5 minutes; repeat on Day 29, 4 cycles.
Assessment of Safety
During therapy, patients are monitored weekly for signs of acute toxic effects, with appropriate adjustments in chemotherapy and radiotherapy made as necessary. Assessment of perioperative and 30-day postoperative complications included anastomotic leakage, perineal complications, bleeding, ileus, fistulas, and death.
Follow-up
Over a follow-up period of 5 years, long-term toxic effects are assessed at 1, 3, and 5 years post treatment. Evaluations consist of physical examination, a complete blood count, and blood chemical analysis. Proctoscopy, abdominal ultrasonography, CT of the abdomen, and chest radiography are also used, according to guidelines of the German Cancer Society.
[1] Histopathological confirmation of local recurrence (defined as a tumor within the pelvis or the perineal scar) and of distant recurrence is encouraged; acceptable alternative approaches included sequential radiologic studies to detect the enlargement of a mass. The physicians evaluating patients' relapse status are aware of the treatment assignments.
Rules for Dose Modification
Toxicity and Adverse Events
Acute toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events, v 3.0 (CTC AE). In case of adverse events which do not result in severe or life-threatening consequences as judged by examining physician (e.g. alopecia), treatment should not be modified. If several different kinds of toxicity occur, the most vigorous dose reduction step should be applied.
If an adverse event can be traced back exclusively on one cytostatic agent or specifically on the radiotherapy (e.g., hand-foot syndrome by continuous 5-FU infusion, neurotoxicity by oxaliplatin) the dose of the other drug or of radiotherapy does not have to be modified. If dose reduction becomes necessary, the reduced dosage will be kept until end of pre-operative chemoradiotherapy or of adjuvant chemotherapy, respectively. A new escalation is not allowed. If toxicity requires therapy interruption of more than two weeks, the patient will be removed from the study for toxicity reasons.
Control arm with 5-FU: Guidelines for dose modifications
During per-operative chemoradiotherapy and between the adjuvant chemotherapy cycles, bone marrow depression, diarrhea, stomatitis and occasionally hand-foot syndrome is expected. Continuation of the chemotherapy might be postponed by one week, however, regarding the pre-operative setting, should be within the radiotherapy frame.
For simultaneous chemoradiotherapy, the following guidelines for chemoradiotherapy have been defined:
• Leucocytes > 3.500 cells/ L and platelets > 100.000 cells/ L: normal dosage
• Leucocytes > 2.500 cells/ L and platelets > 80.000 cells/μL: pause for one week at maximum, if above referenced limits are not reached: switch to 75% of normal dose
• Leucocytes < 2.500 cells/ L and platelets < 80.000 cells/ L: Postponement until limits are reached A dose reduction in the next 5-FU cycle to 75% is also envisaged if the patient exhibits the following side effects:
• Diarrhea > grade 1
• Mucositis > grade 1
• Hand-foot syndrome > grade 1
In case of grade III mucositis, grade III diarrhea, or grade III hand-foot syndrome the 5-FU chemotherapy will be discontinued until only side effects have improved to grade I. Thereafter, 5-FU therapy will be continued with 75% dosage. An exception is diarrhea, which is frequently observed during radiotherapy. In this case, postponement and dose reduction of 5-FU to 75%, as individually judged be the examining physician, should only be performed if grade III diarrhea continues for more than 72 hours despite of proper antidiarrhoic medication. A prerequisite for this procedure is a regular control of the patient, which is usually guaranteed by daily visits at the radiotherapy departments. In case of grade IV toxicity, chemotherapy will be stopped immediately. In this case, restoration of the chemotherapy is only possible after consultation with the study center.
Experimental arm with 5-FU and oxaliplatin: Guidelines for dose modification during pre-operative chemoradiotherapy
The combination of irradiation with 5-FU and oxaliplatin constitutes, with regard to toxicity and recommended dose adjustments, a specific situation in comparison to the established recommendations for dose adjustments for adjuvant or palliative chemotherapy:
1. There are overlapping toxicities of all three agents (in particular, diarrhea, eventually bone marrow toxicity).
2. The typical toxicities of the 5-FU continuous infusion (hand-foot syndrome) and of oxaliplatin (neuropathy) should not occur or at least at minor intensity within the pre-operative setting since the cumulative doses are low.
3. It is always intended not to interrupt radiotherapy and to perform it completely. In general, the dose modifications of the adjuvant setting (see Section 3.4) are also valid for the pre-operative setting.
Experimental arm with 5-FU (+folinic acid) and oxaliplatin: Guidelines for dose modification during adjuvant chemotherapy
If 5-FU or oxaliplatin toxicity at start of an adjuvant chemotherapy cycle necessitates postponement of a treatment cycle, both drugs should be postponed. Treatment should be restored only if both drugs are applicable again. If oxaliplatin has finally to be stopped, treatment should be continued if 5-FU can be given again. If oxaliplatin could not be administered due to toxicity reasons, 5-FU (+folinic acid) is administered at identical dosage (no augmentation!). If 5-FU has finally to be discontinued, the entire chemotherapy will be stopped (i.e., monotherapy with oxaliplatin is not intended).
For dose modifications of 5-FU/folinic acid it is critical whether toxicities occur 1. in the interval between to courses 2. at the day of planned iv application of oxaliplatin and 5-FU or
during infusion of 5-FU
If toxicity occurs in the interval between two chemotherapy courses, upon restoration, dose reduction of 5-FU/folinic acid is performed according to the following table. 
If
• Leukopenia > grade 2
• Thrombocytopenia > grade 1
• Other toxicities > grade 2 are observed at next day of 5-FU/oxaliplatin application, therapy has to be discontinued for one week until normalization of the gastrointestinal toxicity and leucocytes are > 3.000/μl and platelets > 100.000/μl. If these limits are not reached within one week, waiting for another week is recommended. 9 The neurotoxic events caused by oxaliplatin are handled as follows: For a small proportion of patients (1-2%), a specific kind of acute neuropathy is observed, termed laryngopharyngeal dysaesthesia syndrome, which is characterized by subjective feeling of dysphagia and dyspnea without any evidence for objective airway constriction. This syndrome is not life-threatening and rapidly reversible without treatment. In the following cycles, infusion of oxaliplatin should be extended to 6 instead of 2 hours.
The toxicity of oxaliplatin is judged according to the following scale: If hypersensitivity reactions toward oxaliplatin occur, resumption of chemotherapy with oxaliplatin should be considered individually upon careful risk estimations and only if the allergic symptoms were rather mild (consultation with the principal investigator and with the oncological reference center is advised).
Measurement of Treatment Effect including Response Criteria, Definitions of Response and Survival, and Methods of Measurement
Primary Endpoint
The primary endpoint is disease-free survival (DFS) at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.
Secondary Endpoints
Resection rate rate of sphincter preservation t u m o r r e g r e s s i o n cumulative incidence of local and distant recurrences o v e r a l l s u r v i v a l toxicity quality of life
Reasons for early Cessation of Trial Therapy
If toxicity requires therapy interruption of > 2 weeks, the patient will be removed from the study for toxicity reasons.
Throughout the study, patients may be subject to medical assessment and review of compliance before continuing in the study. Patients must continue to meet the inclusion and exclusion criteria during the study, including restrictions related to contraception, if applicable, and medication use. Noncompliant patients may be discontinued from the study.
Every patient will be informed that participation in the study is voluntary and that consent can be withdrawn at any time without the need to provide reasons, and without disadvantage or prejudice.
Objectives and Entire Statistical Section (Including Endpoints)
Statistical Endpoints and Hypothesis
Primary endpoint:
To show superiority of the addition of oxaliplatin to neoadjuvant chemoradiotherapy (N-CRT) and to 5-FU-based adjuvant chemotherapy (experimental arm) in comparison to standard N-CRT followed by adjuvant 5-FU monotherapy (control arm) in terms of DFS within three years of follow-up (primary endpoint).
DFS is defined as the time frame between day of randomization and the first day of occurrence of at least one of the following items:
• R2 resection • local relapse following R0 or R1 resection • evidence of distant metastasis • death of the patient
If none of the aforementioned events occur for a randomized patient within the follow-up time, the patient will be censored at the first day at which at least one of the following events occur:
• end or truncation of the study • study dropout by patient's initiative
The null hypothesis of this study is that there is no statistically significant difference between the experimental and the control arm.
Secondary endpoints were classified as:
• R0 resection rate, circumferential resection margins, quality of TME-surgery • TNM-classification, number of investigated lymph nodes after quality controlled TME-surgery
• proportion of sphincter-preserving surgical procedures • tumor regression grading • cumulative incidence of local relapses and distant metastasis • overall survival after five years • acute toxicity of radio-and chemotherapy according to CTC criteria • late toxicity of radio-and chemotherapy
Sample Size Calculation for the Entire CAO/ARO/AIO-04 Study
In the experimental arm (i.e. the neoadjuvant chemoradiotherapy w ith 5-FU) w ithin the precursor study CAO/ARO/AIO-94, DFS after three years was 74.9% (Fig. 1) . This treatment now serves as control arm and as the basis for sample size calculation of the CAO/ARO/AIO-04 study. When assuming a 82% DFS for the intensified chemoradiotherapy with oxaliplatin and protocol violations of 5% in both treatment arms, about 1200 patients (600 in each arm) will be necessary to achieve a power of 80% at 5% significance level with the log-rank test ( Fig. 2 and Figure 3 ). Sample size estimation was performed as described in Lachin & Foulkes (1986) [2] . 
Figure 3
Power of log-rank test at a significance level of 5% in dependence on diseasefree survival for n=1200 patients.
Analysis cohorts
The 'intent-to-treat' population refers to all randomized patients with the study arm defined by randomization, regardless of protocol violations, stop of treatment, or time of follow-up.
The 'per-protocol' population is composed of all patients who started therapy. The patients will be analyzed in the therapy arm where they were actually treated, regardless of randomization. For the interim safety analyses all randomized patients will be considered who started therapy.
Statistical Analysis
Testing the Primary Endpoint
The hypothesis concerning the primary endpoint, as defined in Section 6.1, is based on the 'intent-to-treat' population assessed by log-rank statistics. The reference distribution under the null hypothesis of equal DFS in both arms will be derived from the asymptomatic conditional distribution of the log-rank statistics for each participating center and in relation to the most prognostic factor, the lymph node status at time of randomization. That corresponds to stratification according to participating centers and dichotomous lymph node status. The effect size is defined by the point estimator with 95% confidence interval of the hazard ratio. If the null hypothesis can be rejected at level of 5%, the experimental treatment will be established. The primary endpoint will be visualized by Kaplan-Meier survival curves.
Interim Analyses
Since planning of the required sample size harbors uncertainties both for methodological reasons such as assumptions of distributions as well as for the estimation of the effect size, a sequential procedure enabling adaption of the study protocol in terms of sample size makes sense. An interim analysis, which is conducted upon minimal follow-up time for half of the patients, could be carried out at the soonest at 3.5 years after start of study, i.e. when the recruitment phase is completed and the last patients have been treated. Therefore, interim analyses have to be restricted on the confirmatory analysis of secondary endpoints referring to treatment safety. These analyses will be performed annually, starting one year after start of study and will result in study stop if a relevant increase in toxicity in the experimental arm is observed (see Section 6.4.4).
In order to postulate superiority of the experimental arm as early as possible and to be able to offer this treatment to newly diagnosed patients, an interim analysis can be conducted if at least 50% of the recruited patients have completed the minimal follow-up time of two years. In this case, the nominal level of 5% will be divided according to Kim and DeMets 1987 [4] . Thereby, data are based on the proportion of patients with completed follow-up time (DeMets 1985 [5] , DeMets 1989 [6] ).
Explorative Analyses
All analyses of secondary endpoints including interim safety analyses are of explorative nature, in particular, no adjustment for multiple testing will be performed. Censored secondary endpoints will be analyzed analogously to the method described in Section 6.4.1. Nominal endpoints will be tested for equivalence in both study arms by means of chi-square statistics derived from contingency tables, ordinal variables by linear statistics. All tests will be performed via stratification for participating center and lymph node status. For visualization, Kaplan-Meier survival curves (in case of censored secondary endpoints) or mosaic plots (in case of contingency tables) will be used.
Safety Analyses
The safety analyses are based on toxicity grades I to V. In general, due to the known neurotoxicity of oxaliplatin a trend to higher toxicity grades i s a s s u m e d , h o w e v e r , t h e following limits must not be exceeded:
• not more than 5 percent absolute increase in grade V toxicity in the experimental compared to the control arm not more than 5 percent absolute increase in grade V toxicity in the experimental compared to the control arm
• not more than 20 percent absolute increase in grade IV toxicity in the experimental compared to the control arm
• not more than 30 percent absolute increase in grade III toxicity in the experimental compared to the control arm
The initial safety analysis will be conducted six months after study begin, if at least 50 patients in each arm have completed therapy, otherwise at that time point at which at least 50 patients in each arm have completed therapy. Thereafter, safety analyses will be carried out annually an refer to the patient cohort as described in Section 6.3.
